{"id":"plk4","name":"PLK4","symbol":"PLK4","route":"/targets/plk4/","asOf":"2026-11-03","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11397","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142731","uniprot":"https://www.uniprot.org/uniprotkb/O00444/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/O00444","open-targets":"https://platform.opentargets.org/target/ENSG00000142731","civic":"https://civicdb.org/genes/10733/summary","oncokb":"https://www.oncokb.org/gene/PLK4","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PLK4","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PLK4","depmap":"https://depmap.org/portal/gene/PLK4?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000142731-PLK4","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/10733","omim":"https://www.omim.org/entry/605031"}],"products":[{"id":"cfi-400945","name":"CFI-400945","status":"phase-2","modality":"Small molecule","route":"/drugs/cfi-400945/"},{"id":"rp-1664","name":"RP-1664","status":"phase-1","modality":"Oral small molecule kinase inhibitor","route":"/drugs/rp-1664/"}],"trials":[{"id":"nct04176848","name":"CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer","nct":"NCT04176848","phase":"2","status":"active"},{"id":"nct03624543","name":"CFI-400945 in Patients With Advanced/Metastatic Breast Cancer","nct":"NCT03624543","phase":"2","status":"active"},{"id":"nct05601440","name":"Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer","nct":"NCT05601440","phase":"2","status":"recruiting"},{"id":"nct03385655","name":"Prostate Cancer Biomarker Enrichment and Treatment Selection","nct":"NCT03385655","phase":"2","status":"active"},{"id":"nct01954316","name":"A Study of CFI-400945 Fumarate in Patients With Advanced Cancer","nct":"NCT01954316","phase":"1","status":"completed"},{"id":"nct06232408","name":"LIONS (PLK4 Inhibitor in Advanced Solid Tumors)","nct":"NCT06232408","phase":"1","status":"historic"},{"id":"nct03187288","name":"Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS","nct":"NCT03187288","phase":"1","status":"completed"}],"pathways":[],"companies":["repare-therapeutics","treadwell-therapeutics"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}